Lisata Therapeutics (NASDAQ:LSTA) Stock Price Down 3.6% – Should You Sell?

Lisata Therapeutics, Inc. (NASDAQ:LSTA)’s share price dropped 3.6% during mid-day trading on Thursday . The company traded as low as $2.06 and last traded at $2.12. Approximately 54,171 shares changed hands during mid-day trading, a decline of 25% from the average session volume of 71,772 shares. The stock had previously closed at $2.20.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Lisata Therapeutics in a research note on Friday, July 17th. Zacks Research upgraded shares of Lisata Therapeutics to a “hold” rating in a report on Monday, May 18th. Finally, HC Wainwright downgraded shares of Lisata Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Reduce” and an average price target of $15.00.

Lisata Therapeutics Trading Down 21.2%

The firm has a market cap of $15.21 million, a PE ratio of -0.90 and a beta of 0.79. The stock has a 50 day simple moving average of $3.29 and a 200-day simple moving average of $3.77.

Lisata Therapeutics (NASDAQ:LSTA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.50) earnings per share (EPS) for the quarter. On average, equities research analysts expect that Lisata Therapeutics, Inc. will post -1.09 EPS for the current year.

Institutional Trading of Lisata Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rangeley Capital LLC acquired a new stake in Lisata Therapeutics during the 1st quarter worth about $376,000. Renaissance Technologies LLC raised its holdings in Lisata Therapeutics by 6.5% in the 1st quarter. Renaissance Technologies LLC now owns 131,715 shares of the company’s stock worth $660,000 after purchasing an additional 8,000 shares during the period. SOL Capital Management CO acquired a new position in Lisata Therapeutics during the first quarter worth $61,000. Deltec Asset Management LLC acquired a new stake in Lisata Therapeutics in the 1st quarter worth about $451,000. Finally, Ground Swell Capital LLC increased its position in shares of Lisata Therapeutics by 64.0% during the fourth quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock worth $73,000 after purchasing an additional 15,213 shares in the last quarter. Hedge funds and other institutional investors own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.